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HPV-16We previously identiﬁed a gene, nuclear receptor-interaction protein (NRIP), which functions as a transcrip-
tion cofactor in glucocorticoid receptor (GR) and human papillomavirus E2 (HPV E2)-driven gene expression.
Here, we comprehensively evaluated the role of NRIP in HPV-16 gene expression. NRIP acts as a transcription
cofactor to enhance GR-regulated HPV-16 gene expression in the presence of hormone. NRIP also can form
complex with E2 that caused NRIP-induced HPV gene expression via E2-binding sites in a hormone-
independent manner. Furthermore, NRIP can associate with GR and E2 to form tri-protein complex to acti-
vate HPV gene expression via GRE, not the E2-binding site, in a hormone-dependent manner. These results
indicate that NRIP and GR are viral E2-binding proteins and that NRIP regulates HPV gene expression via
GRE and/or E2 binding site in the HPV promoter in a hormone-dependent or independent manner,
respectively.
© 2011 Elsevier Inc. All rights reserved.Introduction
We previously identiﬁed a novel gene for a protein we later
termed nuclear receptor-interaction protein (NRIP) (GenBank acces-
sion numbers AY766164 and AAX09330). The NRIP protein is com-
posed of 860 amino acids and 7 WD40 domains, and its expression
is restricted to the cell nucleus (Han et al., 2008; Tsai et al., 2005). Nu-
clear receptor-interaction protein acts to upregulate androgen recep-
tor (AR)- and glucocorticoid receptor (GR)-driven transcriptional
activity of the native mouse mammary tumor virus (MMTV) promot-
er (Tsai et al., 2005). We also identiﬁed NRIP as a novel AR-target
gene and showed that NRIP protects the AR protein from ubiquitin/
proteasome degradation (Chen et al., 2008). Additionally, we also
found that NRIP is a binding protein for human papillomavirus 16
(HPV-16) E2 protein. NRIP acts as a scaffold to recruit E2 and calci-
um/calmodulin to prevent polyubiquitination and degradation of E2
resulting in enhancing E2 stability and E2-driven gene expression
(Chang et al., 2011).
HPV types 16 and 18 (HPV-16 and -18) are the most frequently
identiﬁed viruses in cervical cancer (Ruutu et al., 2006; zur Hausen,
2002). Clinical and epidemiologic evidence indicates that factors in
addition to HPV infection, and not HPV infection alone, cause malig-
nancy (de Villiers, 2003; Hebner and Laimins, 2006; Moodley et al.,
2003). An increased risk of cervical neoplasia has been correlatedrobiology, College of Medicine,
, Taipei, Taiwan. Fax: +886 2
en).
rights reserved.with long-term use of oral contraceptives and pregnancy, and oral
contraceptives containing progestin and estrogen are epidemiologi-
cally associated with increased risk of cervical carcinoma. A recent re-
port also found that estrogen works with HPV oncogenes in the
development of cervical cancer in an animal model (Shai et al.,
2008). Hormones in oral contraceptives facilitate HPV-16–mediated
transformation, and the RU486 steroid antagonist abolishes transfor-
mation induced by dexamethasone (de Villiers, 2003; Moodley et al.,
2003). In addition, the GR has been reported to be a transcription
factor associated with the regulation of HPV gene expression. Gluco-
corticoid treatment increases endogenous HPV-16 E6/E7 gene ex-
pression in SiHa cells harboring integrated HPV-16 DNA (Chan et al.,
1989; Khare et al., 1997) and can induce HPV-16 gene expression
via GR association with 3 glucocorticoid response elements (GREs)
within the HPV-16 long control region (LCR) (Mittal et al., 1993).
Studies of reporter constructs containing the LCR of HPV-11, HPV-16,
or HPV-18 demonstrated that both dexamethasone and progester-
one treatment increase transcriptional activity of the promoters of
these HPV types in cell culture (de Villiers, 2003; Moodley et al.,
2003), but HPV-31 is induced by dexamethasone only in differentiat-
ed cells, not in cancer cell lines (Bromberg-White andMeyers, 2002).
The mechanisms of hormone regulation of HPV gene expression re-
main unclear.
The HPV-16 E2 protein is a multifunctional DNA-binding protein
and a prototypic transcription factor, with an N-terminal
transcription-activation domain and a C-terminal DNA-binding do-
main, separated by a hinge region. Human papillomavirus E2 has a
regulatory function in viral transcription (Giri and Yaniv, 1988) and
can serve as an activator or repressor of transcription, depending on
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et al., 1991; Sousa et al., 1990). There are 4 E2-binding sites within the
HPV LCR. Binding of E2 to promoter-distal sites within the LCR acti-
vates HPV transcription. When HPV E2 proteins bind to promoter-
proximal sites, they function as transcription repressors (Thierry,
2009) because they inhibit Sp1 and TFIID/TBP from binding to their
cognate sequences and hence inhibit assembly of the transcription-
initiation complex. Recently, several cellular proteins have been iden-
tiﬁed that bind directly to E2 and thus regulate HPV gene expression
(Donaldson et al., 2007; Kruppel et al., 2008; Kumar et al., 2007; You
et al., 2004).
Evidence for the roles of cellular factors, including hormones, nu-
clear receptors, nuclear receptor cofactors, and viral E2 interaction, in
HPV gene expression has remained elusive. We previously reported
that NRIP can directly form a complex with the GR (Tsai et al.,
2005) and HPV-16 E2 (Chang et al., 2011). GR has been reported to
interact directly with HPV-16 E2, but the effect of the GR/E2 complex
on HPV gene expression has not been elucidated (Wu et al., 2007a,b).
Therefore, in the present study, we comprehensively evaluated the
interaction of the GR, NRIP, and virus E2 in the regulation of HPV-16
gene expression.Fig. 1. Glucocorticoid activates human papillomavirus gene expression. A) Reverse-transcri
pression in various cervical cancer cell lines. B) Western-blot analysis of GR and NRIP prot
were transiently transfected with HPV-16 LCR plasmid. After 24 h, cells were treated with or
formed. D) SiHa cells were incubated in DMEM supplemented with 5% charcoal/dextran-str
RT-PCR and quantitative PCR analysis. E7 mRNA expression in the vehicle control (EtOH) wa
24 h and then treated with indicated amounts of Dex for 16 h. Total RNA were isolated and an
for three independent experiments (n=3). F) SiHa cells were incubated with DMEM supple
was performed with anti-GR antibody, and precipitated chromatin was ampliﬁed by PCR uResults
Hormone Activation of Human Papillomavirus Gene Expression
To elucidate the mechanism of GR regulation of HPV-16 gene ex-
pression in cells, we compared the GR expression level in different
cervical cancer cell lines by reverse-transcription polymerase chain
reaction (RT-PCR) and Western blotting. SiHa cells, containing an in-
tegrated HPV-16 genome, showed the highest expression of GR RNA
(Fig. 1A) and protein (Fig. 1B), and C33A cells (HPV-negative)
showed no detectable GR expression (Figs. 1A and B). The regulatory
regions of the HPV-16 genome reportedly contain at least 3 GREs
(Mittal et al., 1993). As shown in Fig. 1C, dexamethasone (Dex)
alone activated HPV-16 reporter promoter activity in SiHa cells,
which express a high level of endogenous GR compared to the other
tested cervical cell lines C33A, CaSKi, and HeLa. Therefore, we used
SiHa cells in the following experiments, with C33A cells as a negative
control. The effect of glucocorticoid on endogenous HPV-16 E6 and E7
mRNA in SiHa cells (Fig. 1D) was proportionally higher with increas-
ing Dex concentration. Hence, 10 nM Dex was used for the following
experiments. To further test the response to Dex treatment in Caskiption polymerase chain reaction (RT-PCR) analysis of glucocorticoid receptor (GR) ex-
ein expression in various cervical cancer cell lines. C) Various cervical cancer cell lines
without 10 nM dexamethasone (Dex) for another 16 h, and a luciferase assay was per-
ipped serum (CDS), treated with increasing amounts of Dex for 16 h, and subjected to
s set at 1. E) Caski and HeLa cells were incubated in DMEM supplemented with CDS for
alyzed by qPCR using speciﬁc primers targeted to E7. Data are shown as means and S.D.
mented with 5% CDS. After treatment with or without 10 nM Dex for 16 h, a ChIP assay
sing primers ﬂanking the HPV-16 long control region.
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the results show that 10 nM Dex induces E7 expression in HeLa
(Fig. 1E, right panel) but do not in Caski cells (left). To detect the in-
teraction between endogenous GR and endogenous HPV-16 promoter
in SiHa cells, a ChIP assay was performed, and results showed that en-
dogenous GR bound HPV-16 promoter inserted in the SiHa chromo-
some in the presence of Dex (Fig. 1F). Taken together, hormone can
induce HPV-16 E7 expression in SiHa (Fig. 1D) and 18 E7 in HeLa
cells (Fig. 1E, right) but do not in Caski cells (left). The possible reason
might be that HeLa and SiHa cells have much higher endogenous GR
expression than Caski cells (Fig. 1B).
Mapping of Glucocorticoid Response Element-Binding Sequences in
HPV-16 Promoter that Respond to GR
Three GR-binding sites (GRE1, GRE2, and GRE3) correspond to nu-
cleotides 7385–7400, 7474–7489, and 7640–7655 of the HPV-16 reg-
ulatory sequence, respectively (Chan et al., 1989; Khare et al., 1997).
Treatment with glucocorticoid or progesterone has been shown to ac-
tivate GRE1, GRE2, and GRE3 individually (Chan et al., 1989; Khare et
al., 1997). To systematically identify which GRE plays a major role in
HPV-16 promoter transcriptional activity in response to hormone and
GR, a series of GRE deletion mutants, including 1, 2, or, 3 truncated
GRE mutants in the HPV-16 promoter were constructed, and the lu-
ciferase activity of each mutant was measured. SiHa cells (expressing
a high endogenous amount of GR, as shown in Figs. 1A and B) trans-
fected with the HPV-16 promoter or its mutants and treated with or
without Dex showed the high relative luciferase activity of each pro-
moter mutant triggered by Dex compared to EtOH (vehicle control)
treatment (Fig. 2A). We found that LCR-331, which did not include
the 3 previously reported GRE binding sites, showed 1.8-fold promot-
er activity in the presence of Dex compared to EtOH treatment. ThisFig. 2. A novel fourth glucocorticoid receptor-binding site on the human papillomavirus-16
with 5% charcoal/dextran-stripped serum (CDS) and transiently transfected with a series of
gion (LCR) reporters and with or without RSVT7-hGR. Luciferase assay was performed afte
mean±standard deviation of 3 independent experiments (n=3), *Pb0.05. The ratio refe
each construct. C) It is known that the HPV-16 LCR contains 3 GR response elements (GR
GRE3 (from nt 7640 to nt 7655). The novel putative GRE4, from nt 7700 to nt 7715 of the H
(http://tfbind.ims.u-tokyo.ac.jp) and TFBIND (http://www.cbil.upenn.edu/cgi-bin/tess/tess)
GREs are shown in boldface, and the sequences of mutant forms are underlined. E) Site-dir
papillomvirus-16 LCR luciferase reporters were transfected into SiHa cells, and the cells w
with or without 10 nM Dex for another 16 h. Promoter activity was measured as described
EtOH treatment for each construct. The presented data are the means of three experimentsratio was similar to that for LCR-832, LCR-586, and LCR-497, contain-
ing full-length GRE1, truncated GRE1, and truncated GRE1 and GRE2,
respectively. Likewise, the relative luciferase activity of C33A cells
transfected with GR-expression plasmid and each promoter mutant
and treated with or without Dex was similar to that of LCR-331, and
this enhancement was not observed with LCR-158 (Fig. 2B). These
results imply the presence of a novel GRE in the HPV-16 promoter.
We therefore searched for a novel GRE with BLAST searches of the
HPV-16 promoter on 2 transcription element search Web sites
(TESS and TFBIND) and found a novel putative GRE on the HPV-16
LCR. In addition to the 3 known GREs, this potential GRE was pre-
dicted to be located at nucleotides 7700 to 7715 on the HPV-16 LCR
(Fig. 2C) and was designated GRE4.
To conﬁrm the function of GRE4 and to understand the distinct re-
sponse of each GRE to Dex treatment, we generated each wild-type
GRE and mutated the 3 other GREs by site-directed mutagenesis
(Fig. 2D). Each mutant HPV-16 promoter reporter contained one
wild-type GRE along with point mutants of the other 3 GREs. To in-
vestigate which GRE site responded to Dex, we measured luciferase
reporter activity after introducing each promoter mutant reporter to
SiHa cells with or without Dex treatment. Fig. 2E shows that each of
the 4 GREs responded to Dex stimulation, but the 16LCRnGRE report-
er, containing mutated GRE1, GRE2, GRE3 and GRE4, no longer
showed enhanced HPV-16 LCR, similar to the results obtained with
the deletion mutant LCR-158, lacking the 4 GREs (Figs. 2A and B).
Thus, we found a novel GRE site (nucleotides 7700–7715) for Dex in-
duction in the HPV-16 promoter (Fig. 2C).
Effect of NRIP on GR-mediated HPV Promoter Activity
We previously showed that NRIP directly binds to the GR and en-
hances GR-mediated native mouse mammary tumor virus (MMTV)long control region. A, B) SiHa and C33A cells were incubated in DMEM supplemented
glucocorticoid receptor (GR)-binding site deletion mutants of HPV-16 long control re-
r treatment with or without 10 nM dexamethasone (Dex) for 16 h. Data are shown as
rs to luciferase activity with Dex treatment relative to that with EtOH treatment for
Es), including GRE1 (from nt 7385 to nt 7400), GRE2 (from nt 7474 to nt 7489), and
PV-16 promoter was identiﬁed via search of the Transcription Element Search System
. D) Comparison of nucleotide sequences among each GRE. Consensus nucleotides for
ected mutagenesis of 4 GR-binding sites was generated from the HPV-16 LCR. Human
ere incubated in DMEM supplemented with 5% CDS for 24 h, followed by treatment
above. The ratio refers to luciferase activity with Dex treatment relative to that with
(mean±S.D.; n=3), *Pb0.05.
Fig. 3. Nuclear receptor-interaction protein enhances glucocorticoid receptor-mediated human papillomavirus-16 and -18 promoter activity. A) The schematic shows 4 glucocor-
ticoid (GR)-binding sites on the HPV-16 promoter sequence and 1 on the HPV-18 promoter sequence. B, C) C33A cells were transiently transfected with HPV-16 LCR reporter or
HPV-18 LCR reporter, RSVT7-hGR, and pcDNA-NRIP, as indicated. D) HeLa cells were transfected with HPV-18 LCR reporter, RSVT7-hGR, and pcDNA-NRIP plasmid DNA, as indicat-
ed. After treatment with or without 10 nM dexamethasone (Dex), luciferase activity was measured and the ﬁrst lane was set 1 as a control. The number was counted from three
independent experiments relative to the control (n=3).
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HPV-18 genome reportedly contain 1 GRE, (Fig. 3A). Hence, we de-
termined whether NRIP enhanced GR-mediated transactivation of
HPV-16 and HPV-18 promoters. We found that NRIP enhanced GR-
mediated HPV-16 LCR-832 (Fig. 3B) and HPV-18 LCR-825 (Fig. 3C) pro-
moter activity in a ligand-dependent manner in C33A cells and en-
hanced GR-driven HPV-18 promoter activity (Fig. 3D) but not HPV-16
promoter activity inHeLa cells (data not shown), consistentwith results
of Fig. 1C showing that Dex had no effect on HPV-16 promoter activity
in HeLa cells harboring GR (Fig. 1B). These data imply that tissue-
speciﬁc factors in different cervical epithelial cells play roles in the
assembly of GR-associated transcriptosome complexes and in the tran-
scriptional regulation of variousHPV types. NRIP appears to increase the
transcription of high-risk HPV types (16 and 18) by enhancing GR-
mediated and hormone-dependent transcription.
NRIP enhances HPV-16 promoter activity via binding to GR
To investigate whether NRIP enhances HPV-16 promoter activity
via binding to GR, a ChIP assay was performed with the endogenous
HPV-16 promoter of SiHa cells. As shown in Fig. 4A, endogenous
NRIP was immunoprecipitated, along with HPV-16 promoter, by
NRIP antibody in cells treated with Dex. In addition, ChIP was con-
ducted with GR antibody followed by a second round with NRIP anti-
body to immunoprecipitate the DNA–protein complex (Fig. 4B).
Results indicated that the GR and NRIP complex is located at the
GRE in the HPV promoter. To further conﬁrm that NRIP exerts its cor-
egulatory function via binding to the GR, we knocked down endoge-
nous GR in SiHa cells with small interfering (si)RNA, and the
binding activity of NRIP to the HPV-16 promoter was lost (Fig. 4C,
lower panel), conﬁrming that endogenous NRIP colocalized with en-
dogenous GR on the HPV-16 promoter DNA sequence. In assays to
conﬁrm NRIP binding to the HPV-16 promoter via the GR in C33Acells, which do not contain the GR, results showed that NRIP bound
to the HPV-16 reporter plasmid DNA sequence only in GR-
containing cells (Fig. 4D). To further investigate which GRE site is im-
portant for NRIP associated with GR, C33A cells were transfected with
each mutant reporter plasmid and the expression vector for GR and
ChIP assays were performed. As shown in Fig. 4E, GR associated
with all 4 GRE sites (lanes 4 to 7) but NRIP showed stronger binding
on GRE3 than the other sites (lane 6). To further conﬁrm the NRIP ef-
fect on GR-driven HPV gene expression, we then tested which GRE
sites are important for NRIP targeting via GR to enhance HPV gene ex-
pression. SiHa cells were transfected with each mutant HPV-16 pro-
moter reporter and NRIP or siRNA against NRIP expression plasmid
with Dex treatment. As shown in Fig. 4F and G, only GRE3 could be ac-
tivated by NRIP and diminished by siNRIP in the presence of Dex in
SiHa cells, respectively. In sum, we conclude that the four GREs can
be induced by GR, but NRIP is only more accessible to GR on GRE3
site to activate HPV-16 gene expression.
NRIP Activates HPV 16 Gene Expression Via Interaction with E2 and/or GR
In our previous study, HPV-16 E2 and NRIP can directly associate
into a complex resulting in E2 protein stabilization and enhanced
E2-mediated transcription (Chang et al., 2011). It has been also
reported that the GR directly binds viral E2 and can induce MMTV
promoter activity which contains GRE but no E2 binding sites (Wu
et al., 2007a). To verify NRIP-GR-E2 complex formation, coimmuno-
precipitation analysis was performed using transient cotransfection
of NRIP, GR, and E2 expression plasmids in HEK 293 T cells. Cell ly-
sates were then collected and immunoprecipitated with anti-FLAG,
anti-HA, and anti-EGFP antibodies for NRIP, GR, and E2, respectively.
As shown in Fig. 5A, NRIP could bind to E2 (lane 1) and GR (lane 2);
and NRIP, GR, and E2 might form a tri-protein complex (lane 4).
Also, a two-step coimmunoprecipitation assay with 293 T cells co-
Fig. 4. Glucocorticoid receptor and nuclear receptor-interaction protein are colocalized at the human papillomavirus-16 promoter in the presence of dexamethasone. A) ChIP assays
were performed in SiHa cells using primers speciﬁc for GRE3 on the HPV-16 LCR to assess NRIP association with HPV-16 LCR DNA with or without dexamethasone (Dex). The DNA–
protein complexes were immunoprecipitated with anti-NRIP and anti-IgG antibodies separately and then subjected to semiquantitative PCR. B) To investigate the colocalization of
the glucocorticoid receptor (GR) and NRIP on the HPV-16 LCR, a re-ChIP was performed using chromatin extracts of Dex- or EtOH-treated SiHa cells immunoprecipitated with anti-
GR antibody. Anti-GR immunoprecipitates were reimmunoprecipitated with antibody to NRIP or IgG, and the extracted DNAs were subjected to PCR. C) SiHa cells were transiently
transfected with pSuper-shGR to knock down endogenous GR. Chromatin extracts were then immunoprecipitated with anti-NRIP antibody. Immunoprecipitates were subjected to
PCR analysis using primers ﬂanking the GRE3 site. D) C33A cells were transfected with or without RSVT7-hGR plasmid and treated with 10 nM Dex for 16 h. Chromatin extracts
were immunoprecipitated with antibody to NRIP, and the eluted DNAs were subjected to PCR analysis. E) C33A cells were cotransfected with RSVT7-hGR plasmid and various
site-directed mutant reporters as indicated. After treating with or without Dex for 16 h, Chromatin extracts were immunoprecipitated with antibody against GR. The eluted
DNA–protein complexes were subjected to PCR analysis (ChIP) or further immunoprecipitation with antibody against NRIP (reChIP). F, G) SiHa cells were grown in DMEM supple-
mented with 5% charcoal/dextran-stripped serum for 24 h. Cells were cotransfected with or without pcDNA-NRIP or siRNA against NRIP and HPV-16 LCR or site-directed mutant
reporters as indicated. After 16 h of treatment with 10 nM Dex, luciferase activity was measured as described above. The fold change was measured as the luciferase activity of
each experimental condition compared to that in the absence of expression of NRIP and siNRIP. All are shown as means±S.D. for three independent experiments (n=3), *Pb0.05.
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could bind GR and E2 simultaneously (Fig. 5B), indicating that NRIP-
GR-E2 can form trimeric complex in cells. To investigate the interac-
tion of cellular factors, such as the GR and NRIP, and the viral factor
E2 in the regulation of HPV gene expression, we analyzed the effect
of these three proteins on HPV-16 LCR-832 promoter activity with
or without Dex in C33A cells (lacking GR expression). As shown in
Fig. 5C (lane 14), these three protein complexes stimulated the high-
est HPV gene expression in the presence of hormones compared to
the other factor combinations. Fig. 5C (lane 12) shows the effects of
E2 and GR on HPV promoter activity; these two proteins increased
HPV promoter activity in the presence of hormone; but promoter ac-
tivity in the absence of hormone (lane 11) was similar to that of E2with or without hormone (lanes 5 and 6). Two possibilities can be
considered: E2 may be a cofactor for the GR, or the GRmay be a cofac-
tor for E2. Firstly, to determine whether the GR is a cofactor for E2 and
binds to the E2-binding site via the E2 protein, the four mutated GREs
of the HPV-16 promoter containing wild-type E2 binding sites were
tested. As shown in Fig. 5D, to compare with E2 alone (lanes 7 and
8) to E2 with GR (lanes 3 and 4), the promoter activities have no dif-
ference with or without hormone, indicating that GR is not a cofactor
of E2 on E2-binding sites of HPV promoter. Secondly, to investigate
whether E2 is a cofactor for GR-driven gene expression, we used
MMTV reporter (containing GREs) lacking of E2 response elements
and found that GR and E2 could induce MMTV promoter activity in
the presence of Dex (Fig. 5E, lanes 7 and 8) indicating E2 is a cofactor
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transcriptional complex through GREs to cooperatively stimulate
MMTV promoter activity in a hormone dependent manner (Fig. 5E,
lane12). To further conﬁrm the transcription activity of these three
protein complex via GR as a transactivator, we generated point
mutants of the two E2-binding sites (located at distal promoter
sites) plus containing wild-type GRE3 and mutated forms of the
other three GREs in the HPV promoter backbone (Fig. 5F), due to
the fore-mentioned, NRIP associated with the GR and locating to
GRE3 activates HPV-16 gene expression (Figs. 4F and G). Reporter
promoter activity showed that GR-E2-NRIP had the highest effect
compared to GR-E2 or GR-NRIP in the presence of hormone (Fig. 5F,
compared lane 7 to lanes 5 and 6). Taken together, NRIP-E2 complex
can activate HPV gene expression via an E2-binding site in a
hormone-independent manner (Fig. 5G, upper panel) and NRIP-GR-
E2 trimeric complex bound to GRE3 in a hormone-dependent manner
(Fig. 5G, lower panel).
Knockdown of NRIP Reduces HPV-16 E6/E7 Gene Expression and Results
in Inhibition of Cell Proliferation
It has been reported that siRNA for NRIP inhibits proliferation of
prostate cancer cells (LNCaP) and HPV-negative cells (C33A) (Tsai
et al., 2005). Here, we demonstrated that NRIP enhanced GR- or E2-
mediated gene expression. We then asked whether siNRIP-mediated
knockdown of endogenous NRIP gene expression affects HPV-16 E6/
E7 gene expression in SiHa cells (HPV-16 positive). Cells were treated
with siNRIP (or siGFP as a control), treated with Dex (or EtOH), and
subjected to RT-PCR (Fig. 6A). The effect of siNRIP was conﬁrmed; re-
gardless of Dex treatment, the NRIP mRNA level decreased in a
concentration-dependent manner (Fig. 6A, lanes 5–7 and lanes
12–14). In addition, a decrease in E6/E7 expression was observed in
response to Dex treatment (lanes 12–14), and this coincided with a
decrease in NRIP, but this phenomenon was not observed in the ab-
sence of Dex treatment (lanes 5–7). Although it was mentioned that
NRIP can interact with E2 to regulate HPV gene expression in a
hormone-independent manner, E6/E7 gene expression was not af-
fected by EtOH treatment (lanes 5–7), owing to the lack of endoge-
nous E2 expression in SiHa cells. As to the effect of siNRIP on GR-
mediated cell proliferation, trypan blue exclusion showed that the
proliferation of cells transfected with siGFP, which was the control,
was signiﬁcantly lower than that in cells treated with Dex (Fig. 6B),
indicating that the siGFP control treated with Dex had the highest
proliferation rate. Comparing the effects of treatment with Dex and
EtOH, cells treated with siNRIP/Dex showed a higher proliferation
rate than cells treated with siNRIP/EtOH, indicating GR-mediated
cell proliferation. However, E6/E7 gene expression was not changed,
but the proliferation rate was lower in cells treated with siNRIP/
EtOH compared to control cells treated with siGFP/EtOH, indicating
that NRIP may be involved in gene regulation in addition to that of
HPV. Thus, the decrease in proliferation of cells treated with siNRIP
is consistent with the decrease E6/E7 gene expression in Dex-
treated cells, which is associated with cell transformation (Thomas
et al., 2008).
Discussion
In the present study, we comprehensively evaluate the role of the
GR in HPV-16 gene expression. First, we identiﬁed a novel GRE site for
glucocorticoid induction (GRE4), located at nucleotides 7700 to 7715
of the HPV-16 promoter, by transient transfection assays of point mu-
tants of HPV promoter, concluding that there are four GRE sites that
can be induced by the GR plus hormone (Fig. 2). We further deter-
mine that NRIP forms a complex with the GR and binds GRE3 within
the HPV-16 promoter to stimulate HPV gene expression in a
hormone-dependent manner (Figs. 4F and G). In addition to NRIPacting as a cofactor for the GR (Fig. 3), we also ﬁnd that E2 acts as a
transcription cofactor for the GR (Fig. 5E, lane 8 and Fig. 5F, lane 5).
Plus we determine that GR associated with NRIP only targets GRE3
among the four GREs within the HPV-16 promoter, implying that
the GRE3 site possesses the best physical structure for GR complex
proteins binding, even though there are four GREs that respond to
glucocorticoid. This is consistent with the results of the Bernard
group, who ﬁrst identiﬁed a GRE site located at GRE3 on the HPV-16
LCR and showed its binding by DNaseI footprinting and DMS protec-
tion assays using partially puriﬁed GR from rat liver (Gloss et al.,
1987). Later, the Pater group identiﬁed GRE1 and GRE2 in in vitro in-
teraction assays, including mobility-shift assays with HeLa whole-cell
extracts and oligonucleotide probes, ultraviolet crosslinking assays,
and Southwestern blotting (Mittal et al., 1993).
Interestingly, GRE deletion mutations of HPV promoter increase
basal level of luciferase expression either in SiHa cells (Fig. 2A) or in
C33A cells (Fig. 2B), but substitution mutations reduced it dramatical-
ly (Fig. 2E). The activity of HPV-16 promoter is under control of many
different transcription factors and the surrounding chromatin struc-
ture. These various factors binding sites locating from GRE1 to GRE4
including matrix attachment region, epithelial-speciﬁc enhancer,
NF1, AP1 and TEF binding sites (Apt et al., 1993; Chan et al., 1989;
Chang et al., 2011; Chong et al., 1990, 1991; Gloss et al., 1987,
1989). The substitution mutants containing sequences altered in
these regions might affect basal promoter activities. Similarly, our
previous studies showed that overexpression of GR and NRIP in
C33A cells supports activation of LCR-79 reporter (containing only
GRE1) by Dex. It seems that the short backbone is more accessible
for transcription factors or cofactors than the entire HPV promoter.
It is interesting to further investigate GR binding efﬁciency to deletion
and substitution mutants of HPV promoter.
We previously demonstrated that GR can interact with NRIP en-
dogenously (Tsai et al., 2005). Here we illustrate that GR cooperates
with NRIP to activate HPV gene expression in a ligand-dependent
manner by in vitro luciferase promoter assays (Fig. 5C, lanes 7 and
8), plus NRIP endogenously colocalizes with GR on HPV-16 promoter
with Dex treatment in SiHa cells (Figs. 4A and B). Taken together,
those indicate that GR enters into nucleus by treating with glucocor-
ticoid and then binds with nuclear NRIP to stimulate HPV gene ex-
pression. Regarding the effects of E2 and GR on HPV promoter
activity, our data demonstrate that E2 can be a cofactor for GR in a
hormone-dependent manner to induce HPV gene expression
(Fig. 5C, lanes 11 and 12). However, GR is not a cofactor for E2 in
hormone-independent due to there is no difference with or without
hormone by the four mutated GREs of the HPV-16 promoter contain-
ing E2-binding sites were used to test (Fig. 5D, lanes 3–4 with lanes
7–8). Moreover, these three proteins could form trimeric complexes
to cooperatively induce HPV gene expression locating on GREs via
hormone-dependent pathway (Fig. 5C, lane 14; Fig. 5E, lane 12; and
Fig. 5F, lane 7). And only E2 and NRIP complex located E2-binding
sites through hormone-independent pathway to stimulate HPV gene
expression (Fig. 5D, lanes 9–10 with lanes 11–12).
In the previous study, we reported that NRIP is an E2-binding pro-
tein. Binding of the E2 and NRIP complex to the E2-binding site on the
HPV-16 promoter induces HPV gene expression in a hormone-
independent manner (Chang et al., 2011). Recent reports have identi-
ﬁed several cellular proteins that directly bind E2, including TFIIB
(Yao et al., 1998), Brd4 (Gagnon et al., 2009; Lee and Chiang, 2009;
You et al., 2004), Tax1BP1 (Wang et al., 2009), Brm (Kumar et al.,
2007), Mdm2 (Gammoh et al., 2009), and p300 (Hadaschik et al.,
2003; Kruppel et al., 2008), to regulate HPV gene expression, E2 pro-
tein stability, or maintain viral episomes in HPV-infected cells (You et
al., 2004). We add NRIP as an E2-binding protein and report that NRIP
is a transcription cofactor of both the GR and E2 to enhance GR- and
viral E2-mediated HPV gene expression in a hormone-dependent
manner and a hormone-independent manner, respectively (Fig. 5G).
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Fig. 6. Knockdown of endogenous nuclear receptor-interaction protein results in decreased mRNA expression of E6 and E7 and inhibits proliferation activated by dexamethasone.
A) SiHa cells were incubated in the absence of hormone-containing medium for 24 h, followed by transfection with pSuper-shNRIP. After 24 h, cells were treated with or without
10 nM dexamethasone (Dex) for another 6 h. Total RNA was isolated, and endogenous NRIP, E6, E7, glucocorticoid receptor (GR) and β-actin gene expression were subjected to
semiquantitative PCR analysis. B) SiHa cells were seeded at 2×104 cells per well into 24-well plates and transfected with pSuper-shNRIP, or pSuper-shEGFP as a control, with
Lipofectamine. After plating and maintaining the cells in medium without hormone for 24 h after transfection, cells were treated with or without Dex every 24 h. Total cell
numbers were counted at 0, 24, 48, 72, and 96 h using a hemocytometer and trypan blue exclusion. All experiments were performed 3 times in triplicate. Data are expressed as
mean±standard deviation.
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scription cofactors to recruit chromatin-modifying and -remodeling
factors for the regulation of HPV-16 gene expression. Since NRIP con-
tains 7 WD40 domains (Tsai et al., 2005), and recent reports have
shown that WD40-containing proteins can interact with histone
methyltransferase to regulate chromatin remodeling for transcription
(He et al., 2006; Higa et al., 2006; Wysocka et al., 2005). Our previous
report demonstrated that NRIP is a cofactor of the AR to enhance an
AR-driven prostate-speciﬁc antigen gene expression (Chen et al.,
2008; Tsai et al., 2005). Several reported transcriptional cofactors of
AR (e.g., ARA54, ARA55, ARA70, ARA160, FHL2, the p160 family, and
CBP/p300) can form multiprotein complexes, facilitating access to
AR and facilitating the function of the RNA polymerase II core
machinery to target DNA by chromatin remodeling and histoneFig. 5. Nuclear receptor-interaction protein acts synergistically with E2 and the glucocortic
fected into HEK 293 T cells, which were cultured in FBS medium. After 48 h, cell lysates we
for E2, NRIP, and GR respectively. Immunoprecipitates were then subjected to Western bl
the upper. 293 T cells were co-transfected with NRIP-FLAG, HA-GR and EGFP-16E2 and c
were eluted with 3×FLAG peptide and eluates were then immunoprecipitated with anti-E
pcDNA-NRIP, and pSG5-HA-16E2 plasmids, as indicated. After treating with or without 10 n
tion of activity was compared with that of reporter alone. Data are the means of three expe
MMTV-Luc or 16LCR-nGRE reporter with RSVT7-GR, pSG5-HA-E2, and pcDNA-NRIP, as ind
(Dex) for 16 h, and luciferase activity was measured and normalized. Data are show
16LCRwGRE3m34E2E-Luc reporter has mutated E2 response elements 3 and 4 retains wild-
siently cotransfected into C33A cells with RSVT7-GR, pcDNA-NRIP, and pSG5-HA-E2, as indi
sured. Data are shown as the mean±SD of three independent experiments (n=3), *P
interacting with E2 and regulated E2-mediated transcriptional activation in the absence of D
with GR. This complex regulated the expression of E6/E7 gene by colocalizing on GRE3.modiﬁcation (Aarnisalo et al., 1998; Berrevoets et al., 1998;
Fujimoto et al., 1999; Heinlein et al., 1999; Hsiao and Chang, 1999;
Kang et al., 1999; Muller et al., 2000). This study along with our pre-
vious report, we conclude that NRIP is not a DNA-binding protein but
acts as a scaffold to recruit the transcriptosome to DNA-binding pro-
teins to regulate target gene expression. In the case of HPV-16, NRIP
interacts with viral DNA binding protein such as GR and/or E2 to
stimulate HPV gene expression.
We also previously reported that NRIP protects the AR protein
from ubiquitin/proteosome degradation, inducing AR-driven gene
expression (Chen et al., 2008). Recent reports have shown that
the DDB1-Cullin4-ROC1 complex plays an E3 ligase function for
the degradation of various proteins. NRIP is also known as DCAF6
or IQWD1, so named by other researchers who reported thatoid receptor. A) Plasmids pCMV-HA-GR, pEGFP-E2, and p3XFLAG-NRIP were cotrans-
re collected and immunoprecipitated with anti-GFP, anti-Flag, and anti-HA antibodies
otting. B) The procedure of two-step coimmunoprecipitation is outlined in the box at
ell lysates were ﬁrst precipitated with anti-FLAG or mouse IgG antibodies. Samples
GFP antibody. C) C33A cells were cotransfected with HPV-16 LCR reporter, RSVT7-GR,
M dexamethasone (Dex) for 16 h, luciferase activity was measured, and the fold induc-
riments (mean±standard deviation; n=3). D, E) C33A cells were cotransfected with
icated. Twenty-four hours after transfection, cells were treated with dexamethasone
n as the mean±S.D. of three independent experiments (n=3), *Pb0.05. F) The
type glucocorticoid receptor response element (GRE) 3. The reporter plasmid was tran-
cated. After treatment with or without 10 nM Dex for 16 h, luciferase activity was mea-
b0.05. G) Nuclear receptor-interaction protein enhanced HPV promoter activity via
ex. In the presence of ligand, E2 and NRIP may serve as coactivators and form a complex
46 S.-W. Chang et al. / Virology 423 (2012) 38–48DCAF6/IQWD1 binds the Cul4-DDB1 complex, but the function of
this has not been elucidated. Both DDB1 and NRIP contain WD40 re-
peats, but the role of NRIP in protein stability remains unclear.
However, NRIP was reported to directly bind with calmodulin in
the presence of calcium through its IQ domain, resulting in de-
creased E2 ubiquitination and increased E2 protein stability
(Chang et al., 2011). In general, the transcriptional regulatory sys-
tem and the ubiquitin-proteasome system are two major target-
selective systems that control intracellular protein levels in order
for transcription to proceed. Recent reports have indicated that
HPV E2 ubiquitination may involve the regulation of E2-mediated
transcriptional activity. For example, Mdm2, an E3 ubiquitin ligase,
is an E2-interaction protein that acts to enhance E2 transcriptional
activity; mutant Mdm2 lacking ubiquitin ligase activity is unable
to increase E2 transcriptional activity (Gammoh et al., 2009). The
other E2-binding protein, Tax1BP1, binds ubiquitin to prevent pro-
teasomal degradation and promotes E2-dependent transcriptional
activity (Wang et al., 2009). How NRIP serves as a transcription co-
factor to recruit transcription-related factors and/or as a speciﬁc
adaptor for recruiting E2-ubiquitin–conjugating enzymes to viral
E2 or other targets (such as GR) to regulate HPV gene expression re-
quires additional research.
A decrease in NRIP gene expression could decrease HPV-positive
cancer cell proliferation. Changes in cell number are the sum of pro-
liferation and cell death. Our unpublished data show that siNRIP can
induce apoptosis. It was also reported that the reducing E6/E7 ex-
pression in HPV-positive cells results in p53 accumulation and de-
creasing Rb phosphorylation, thereby reactivating cell cycle arrest
and apoptosis (Yew et al., 2011). According to the results of Fig. 6,
siNRIP treated HPV-containing cells can reduce E6 and E7 expres-
sion which is hormone-dependent. In addition to our previous stud-
ies, a study of NRIP silencing showed a decrease in proliferation of
HPV-negative cells such as C33A, HEK 293, and LNCaP cells (Tsai
et al., 2005). A possible explanation might be that NRIP functions
through pathways other than GR and E2 and plays more important
roles in relation with other transcription factors to modulate cell
proliferation. This would indicate that there are several genes tar-
geted by NRIP. Among them, the HPV promoter is one involving
NRIP-targeting via the GRE or E2-binding site. In addition to HPV-
positive cervical cancer, the potential therapeutic effects of siNRIP
may be broadly expanded to include HPV-negative cancer cells. Ad-
ditional NRIP-interacting proteins and NRIP-regulated genes will
need to be identiﬁed to further understand the role of NRIP in
carcinogenesis.
In conclusion, there are four GRE sites that respond to glucocorti-
coid. NRIP interacts directly with the GR, E2, or both to regulate HPV
gene expression. We propose a model of HPV-16 promoter-associated
regulation of virus gene expression in which the GR-NRIP and GR-
NRIP-E2 complexes bind only GRE3 in a hormone-dependent man-
ner, and the E2-NRIP complex binds the E2-binding site in a
hormone-independent manner (Fig. 5G). This is the report of hor-
mone and virus E2 regulation of HPV gene expression.
Material and Methods
Plasmid Construction
The pSG5-HA- 16E2 and 4XE2E-Luc plasmids were the kindly gifts
from Dr. Shih-Ming Huang (National Defense Medical Center, Taipei,
Taiwan) and RSVT7-GR, NRIP-FLAG, pcDNA-NRIP, EGFP-E2 plasmids
were described previously (Chang et al., 2011; Chen et al., 2008; Tsai
et al., 2005). HA-tagged full-length GR was cloned in frame into the
pCMV-HA (Clontech) vector by PCR ampliﬁcation using speciﬁc primers
containing restriction sites. The HPV-16-LCR-832 and HPV-18-LCR-825
repoter plasmids were constructed by polymerase chain reaction (PCR)
ampliﬁcation of the HPV-16 LCR from −1 to −832 of the HPV-16genome or HPV-18 LCR from −1 to −825 of the HPV-18 genome (a
kind gift from Dr. zur Hausen H., Deutsches Krebsforschungszentrum,
Heidelberg, Germany), respectively. A full-length 16LCR-832 DNA was
served as a template to generate truncated ARE/GRE1, GRE2, GRE3,
and GRE4 mutants by PCR-based approaches. The reporters including
16LCRwGRE1, 16LCRwGRE2, 16LCRwGRE3, 16LCRwGRE4 and
16LCRnGRE have entire HPV-16 promoter sequences with point muta-
tions and themutated sequences are presented in Fig. 2D. The distal two
E2 response elements of 16LCRwGRE3m34E2E-Luc reporter plasmid
were mutated and generated from 16LCRwGRE3 by using PCR based
site-directed mutagenesis.
Cell Culture
SiHa, HeLa, and C33A cells were maintained in Dulbecco's modi-
ﬁed Eagle's Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), and 1% of MEM non-essential amino acids solution
(Invitrogen, Grand Island, NY, USA). CaSki and HaCaT cells were
maintained in RPMI 1640 medium supplemented with 10% FBS,
2 mM L-glutamine, 10 mM HEPES, 1.0 mM sodium pyruvate, and
antibiotics.
Transfection and Luciferase Assay
Prior to transfection, cells were seeded in 24-well plate at a densi-
ty of 1×105 per well in DMEM with 5% dextran-coated charcoal-
stripped FBS (DCCS-FBS) (HyClone) for 24 h. Transient transfections
were performed using lipofectamine 2000 (Invitrogen) with 300 ng
of various reporter plasmids, 600 ng of pcDNA-NRIP, 20 ng of
RSVT7-GR, 100 ng of pSG5-HA-E2 and pRL-CMV as internal control.
The total amount of plasmid transfected per well was kept constant
by adding empty pcDNA3.0 vector as needed. Twenty-four hours
after transfection, the medium was replaced by medium with or
without dexamethasone (Dex). After another 16 h, cells were har-
vested and the luciferase activity was measured using the Dual-Glo
luciferase system (Promega) and normalized according to the in-
structions from the manufacturer.
Co-immunoprecipitation
Cells were collected and lysed on ice for 15 min in lysis buffer
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 20 mM NaF, 50 mM Na3VO4,
1% Triton X-100, 10% glycerol, 2 mMdithiothreitol [DTT], 1 mMphenyl-
methylsulfonyl ﬂuoride [PMSF] and protease inhibitor cocktail). The su-
pernatants after sonication were collected after centrifugation and
incubated in IP-buffer (Chang et al., 2011) with respective antibodies
for 2 h at 4 °C. The protein A/G-sepharose beads were added and incu-
bated for further 2 h and then washed with wash buffer (50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 0.5% NP-40, 2 mM EDTA and 1 mM PMSF)
for three times. Co-immunoprecipitated proteins were resolved by
SDS- PAGE and detected by western-blotting. The following antibodies
were used: anti-FLAG (M2; Sigma), anti-GFP (B-2; Santa Cruz), anti-HA
(4 C12; Abcam), anti-GR (H-300; Santa Cruz), anti-GST (1–109; Santa
Cruz), anti-β-actin (Sigma) and anti-NRIP (Abcam).
Chromatin Immunoprecipitation Assays
Forty-eight hours post-transfection, cells were ﬁxedwith 1% formal-
dehyde at room temperature for 10 min and washed with phosphate-
buffered saline and lysed in lysis buffer (1% SDS, 5 mM EDTA, 50 mM
Tris–HCl, pH 8.0, and protease inhibitor cocktail). The collected cell
lysates were subjected to sonication, centrifugation and be diluted 10-
fold in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris–HCl, pH 8.0). After incubating overnight at 4 °C with the
indicated antibodies, the protein A/G-Sepharose beads preblocked
with sheared salmon sperm DNA (Upstate) were added and incubated
47S.-W. Chang et al. / Virology 423 (2012) 38–48for further 2 h. The beads were washed sequentially in low-salt buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.0,
150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton-X100, 2 mM
EDTA, 20 mM Tris–HCl, pH 8.0, 500 mM NaCl), LiCl buffer (0.25 M LiCl,
1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris–HCl, pH 8.0) and
Tris-EDTA buffer. The protein–DNA complexeswere elutedwith elution
buffer (1% SDS, 0.1 M NaHCO3) and reverse cross-linked overnight at
65 °C. DNA was recovered by PCR puriﬁcation kit (Qiagen) and sub-
jected to PCR ampliﬁcation by the following primers: (16LCR-F),
5′-CTT GCC ATG CGT GCC AAA TCC CTG-3′; (16LCR-R), 5′-GTA TGT
AAG GCG TTG GCG CAT AGT G-3′.
RNA Extraction and Semi-quantitative RT-PCR Analysis
Total RNA was extracted using TRIzol reagent (Invitrogen). For re-
verse transcription polymerase chain reaction (RT-PCR), the RNA
(1 μg) from each sample was reverse-transcribed using M-MLV re-
verse transcriptase (Invitrogen). 2 μl of cDNA was ampliﬁed by PCR
using the Expand High Fidelity PCR System (Roche). The following
forward and reverse primers were used: (NRIP-F), 5′-ATG TCT CGG
GGT GGC TCC TAC CCA CAC-3′; (NRIP-R), 5′-ACT GGT TCA CCT GTC
CCT GGT TTG G-3′; (GR-F), 5′-CTC ACT GGC TGT CGC TTC TCA-3′;
(GR-R), 5′-GTC TGA TCT CCA AGG ACT CTC-3′; (HPV-16 E6-F), 5′-
CAC CAA AAG AGA ACT GCA ATG TTT C-3′; (HPV-16 E6- R), 5′-CAG
CTG GGT TTC TCT ACG TGT TC-3′; (HPV-16 E7-F), 5′-ATG CAT GGA
GAT ACA CCT ACA TTG-3′; (HPV-16 E7- R), 5′-TTA TGG TTT CTG
AGA ACA GAT GG-3′; (β-actin-F), 5′-ACC TTC AAC ACC CCA GCC
ATG-3′; (β-actin-R), 5′-CTG GAA GAG TGC CTC AGG GCA-3′. These
primers amplify, respectively, the 1427 bp of the N-terminal region
of NRIP, 511 bp of the N-terminal region of GR, full-length of HPV-
16 E6 and E7, and 414 bp of the β-actin fragment, the relative amount
of which was used as control to determine the amount of total RNA in
each sample. For real-timePCR, theprimers for E7 andGAPDHgenewere
as follows: (qHPV16E7-F), 5′-AAG TGT GAC TCA CGC TTC GGT T-3′;
(qHPV16E7-R), 5′-GCC CAT TAA CAG GTC TTC CAA A-3′; (qHP18E7-F),
5′-CGT CGC AAC ATT TAC CAG CCC GAC G-3′; (qHP18E7-R), 5′-GAA
TGC TCG AAG GTC GTC TGC-3′; (GAPDH-F), 5′- TCA CCA TCT CCA GGA
GCG -3′; (GAPDH-R), 5′-CAG TGA GGC ATG GAC TGT-3′.
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